GALT Galectin Therapeutics Inc

$GALT 1. Early 2026 Summit Therapeutics requested increase in shares. Then announced a partnership in Sept with AstraZeneca for $2 bil (12% stake). They were in Phase 3 2. Early 2024, Novavax requested an increase in shares. In May 2024, before the meeting, company announced a $1.2 bil licensing agreement w/ Sanofi (4.9% stake). They were in Phase 2 3. In 2022, Horizon Therapeutics announced a meeting requesting an increase in shares. In Dec 2022 company acquired by Amgen for $27.8 bil. FDA approved drugs and multiple in Phase 1/Phase 2 4. Brickell Biotech scheduled meeting to vote on RS and increase in shares from 300 to 525 million in May 2022 . Before the meeting, a definitive purchase agreement by Botanix Pharmaceuticals. They were in Phase 3 5. Late 2022 CinCor Pharma sought out either issuance of new shares or execution of a dilutive secondary offering to fund ongoing trials. In January 2023, the company was acquired by AstraZeneca for $1.8 bil. They were in Phase 2 Is there more?

$GALT Galt has a partner, they vote on a 3 million share distribution package to the remaining employees of GALT in December, this is the last thing you do before you sell or partner up give a ton of shares to you and your co-workers Once 3rd trial is approved they will announce, remember they don’t have enough money on hand to fund a 3rd trial.

$GALT I'm convinced there will be a buyout. Looking for golden parachutes, I see with this Omnibus increase proposal the execs will increase the last RSU from 4M to 7M, that's their parachute, no doubt to clear immediately on acquisition. The timing of this all is not coincidence, FDA alignment in June, submittal of abstracts to the liver conference on Nov 5, submittal of P3 protocol with 30 day turnaround time aligns perfectly.

$GALT Upcoming liver meetings should be very good to us. My sense is that we are receiving greater acceptance of our drug by liver KOLs and industry leaders. Also appears to be doubts developing as to how well RESM works (see recent, including today, MDGL stock plunge). Just my opinions, not investment advice.

$GALT FIGHT BACK AGAINST THESE PEOPLE SPREADING FALSE INFORMATION. In ts Q1 filing GALT said it currently did not have plans or funding to undertake another clinical trial and reiterated dependence on strategic partnerships and outside capital. The additional room for shares in today's filing is obviously for a strategic partner to buy-in. GALT is not going on a hiring spree to run p3 on their own, it will use the manpower of the big pharma partner. Connect the dots.

$GALT short term trend lines meet this Thursday, if we get disappointed yet again down to mid $2's may be in play. In the event of a pullback would like to see 200DMA ($3.30) hold. Expecting just a Phase 3 submittal PR. Hoping for partnership/BO, which hopefully comes at the same time...but may come in the days or weeks following Phase 3 PR. If we don't get anything at all, low $1's wouldn't surprise me. Retail is tired of getting the run around, investor sentiment is down, and the market being in the gutter does us no favors.

$GALT when I get stupid rich some day. I’m going to retire and start making AI movies. I’m already working on my first one.

$GALT Joel gets LOADS of credit here. This is what we call a well-run company. Not based on hype and fluff. Methodical and calculated. In the social media era many people fall for who can shout louder. We are fortunate to have a CEO who does not pay attention to the hysteria and does his job the right way. Thats why we are in this position. Thank you JL for getting us here

$GALT Holding up very well. Looking forward to developments over the next three-four weeks- FDA P3 trial protocol response, AASLD meetings etc. Remain very optimistic about our chances. Good luck to all fellow investors.

$GALT https://www.cnbc.com/2026/10/13/martin-shkreli-ftc-pharma-contempt.html The government should investigate who was paying Martin to bring attention to certain biotech companies and why. Doesn’t take a rocket scientist to see Martin was a hired gun. For who is the question?

$GALT That phase 3 should be a confirmational outcomes trial with AA approved when the trial begins. Similar to what Madrigal did but using a hard clinical endpoint to fulfill subpart H and not a BS surrogate biopsy.

$GALT Assuming on September 30th, the Company has submitted a registrational protocol for the Phase 3 trial of belapectin for the prevention of disease progression in patients with MASH cirrhosis and portal hypertension to the U.S. Food and Drug Administration (FDA). If everything is cleared, they may start Ph3 in November, 2026. Most of the time, the company has to hired more employees to prepare for ph3 study. But at this time, still have no openings and don’t have enough money to start ph3 by themselves? FDA green light 🚥 then announce partnership or BO? Pick your choice.

$GALT One has to take a step back and look at the overall landscape. The Journal of Hepatology has an article in press "EASL-EASD-ESMO guidance on the use of resmetirom and semaglutide in MASH targeted therapy." As stated in the abstract- "In adults with MASH cirrhosis, resmetirom or semaglutide appear safe but should not be used as MASH- targeted treatment until further data establish liver- related benefits." My opinion- unrelated to liver related benefits, safety for cirrhosis use is very unclear with these agents, as well as the FGF21 agents that were bought out by BP. I see no other new therapeutic agents for cirrhosis in the 2026 AASLD abstracts. I believe we stand alone. Good luck to all.

$GALT $XBI The short sell manipulator getting his ass back in jail soon. The filing asks the judge to order Shkreli's sister, Leonora Izerne, and his "significant other, Chelsea Voss," to preserve all evidence relating to potential violations of the injunction against Shkreli because both women "appear to have assisted or be assisting Shkreli in violating the Permanent Injunction." https://www.cnbc.com/amp/2026/10/13/martin-shkreli-ftc-pharma-contempt.html

$GALT Blocking a couple of posters now whose posts are, for the most part, worthless to me. It's one way to elevate my reading experience on this board.

$GALT RIchard U might be working on a much larger announcement to go with the FDA submission

$GALT Step 1 = BTD. Breakthrough Therapy Designation gets Galectin more frequent/intensive FDA touchpoints and buys them the ability to negotiate what counts as an adequate AA endpoint before they file, rather than finding out at review. This is the same move Merck, BMS, etc. make before filing an oncology AA on a response-rate or PFS surrogate BTD doesn't approve anything, it changes who's in the room when the endpoint gets negotiated. Step 2 = the endpoint pitch. With that negotiating position, the filing becomes: "prevention of incident esophageal varices in compensated MASH cirrhosis without baseline varices" is the Subpart H endpoint. It was reached at p=0.04 in the pre-specified per-protocol population the one clean statistically significant result out of NAVIGATE, playing the same role a positive secondary/subgroup result plays in an oncology surrogate package.

$GALT When there is deal making with big pharma, things get -quieter- and then you wake up one morning to pleasant surprise news. When there is deal-making underway there is no PR every week. Some posters here don’t understand how it works.

$GALT not a large add, but I am adding another $2000 here this week. That will take me over 16k shares in size and I will be pushing to hit 20k shares before end of November unless we get a substantial event before then.

$GALT Share price is holding up while waiting, despite a correction in the overall market. A good sign.